N/A Completed N=126 Randomized Single-blind Prevention

Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments

Colon Cancer Screening · Colon Polyps · Colon Adenomas · Water Exchange Colonoscopy

Source: ClinicalTrials.gov NCT02665741 ↗

Enrolled (actual)

126

Serious AEs

0.0%

Results posted

Jun 2020

Primary outcomePrimary: Adenoma Detection Rate — 52.4; 40.5; 54.8 percentage of adenomas detected

Summary

The goal of this study is to compare two FDA approved distal colonoscope attachment devices, in order to identify which device can increase adenoma detection rate the most without increasing procedure time or risk.

Outcome Measures

Outcome	Result	p-value
PRIMARY Adenoma Detection Rate	52.4; 40.5; 54.8	—
SECONDARY Proximal Adenoma Detection Rate	45.2; 35.7; 50.0	—
SECONDARY Cecal Intubation Rate	100; 100; 100	—
SECONDARY Withdrawal Time	12.9; 12.4; 13.0	—

Eligibility Criteria

Inclusion Criteria

At least 50 years old
Presenting for a screening or surveillance colonoscopy at UC Davis Endoscopy Suites

Exclusion Criteria

Age less than 50 years
Prior history of colon cancer
Patients with inflammatory bowel disease
Patients suspected to have colon cancer based on non invasive tests such as stool tests for hemoglobin or DNA, or imaging finding suggestive of colon cancer (CT or barium enema).
Patients undergoing colonoscopy for evaluation of symptoms such as abdominal pain, rectal bleeding, diarrhea, constipation, etc, or patient with iron deficiency anemia suspected to be due to ongoing bleeding inside the colon
Patients with family history of colon cancer in 1st degree relative below the age of 60
Patients with family history of hereditary polyposis syndromes such as Lynch syndrome, familial adenomatous polyposis etc, which are associated with an increased risk of colon cancer
Patients unable to consent
Pregnant patients
Incarcerated patients
Non-English speakers

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02665741). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.